Screening and Diagnosis

Opening Story

James, a 58-year-old high school teacher, went to his doctor for a routine checkup. He felt perfectly fine — no pain, no urinary problems, nothing unusual. His doctor mentioned it was time to talk about prostate cancer screening. "But I feel great," James said. "Why would I need a test for cancer?" His doctor explained that prostate cancer often grows silently, without any symptoms at all, and that catching it early — when it is most treatable — is the whole point of screening. After a conversation about the benefits and risks, James decided to get a PSA blood test. His PSA came back at 5.2 ng/mL. That number started a journey of additional tests that ultimately led to an early diagnosis and successful treatment. James later said, "I'm glad my doctor brought it up. I never would have asked on my own."

What Is Screening and Why Do We Screen?

Screening means testing for a disease before you have any symptoms. The goal is to find cancer early, when it is small, confined to the prostate, and most likely to be cured. Not all cancers need treatment — some grow so slowly they may never cause harm — but some are aggressive and can spread if not caught in time. Screening helps sort out which situation you may be in.

The challenge with prostate cancer screening is balance. On one hand, screening can save lives by catching dangerous cancers early. On the other hand, it can also find slow-growing cancers that would never have caused problems, leading to unnecessary worry, biopsies, and sometimes treatments with side effects.¹ ² This is why screening is not a simple "yes or no" — it is a conversation between you and your doctor, weighing your personal risk factors, values, and preferences. This process is called shared decision-making.¹ ² ³

How Do We Screen? The Two Main Tools

1. PSA Blood Test (Prostate-Specific Antigen)

PSA is a protein made almost exclusively by prostate cells — both normal and cancerous. A simple blood test measures how much PSA is in your blood. Higher levels may suggest a problem, but PSA is not a perfect test.⁴ ⁵

Think of PSA as a smoke detector. It tells you something might be going on, but it does not tell you whether there is a real fire (cancer) or just burnt toast (a benign condition like an enlarged prostate or an infection). PSA is sensitive (it picks up most problems) but not very specific (many things besides cancer can raise it).⁴

Key facts about PSA:

• PSA is produced by all prostate cells, not just cancer cells. Small amounts can also be found in other tissues, but the prostate is by far the main source.⁵
• There is no single "normal" number that applies to everyone. The level that triggers concern depends on your age, prostate size, medications, and other factors.⁶
• Not every PSA increase means cancer. And while most prostate cancers produce PSA, rarely some cancers do not raise PSA at all.⁵
• Small variations exist between different laboratory test kits. It is best to have your PSA checked at the same lab each time so results can be compared accurately.⁵

2. Digital Rectal Exam (DRE)

The prostate sits right in front of the rectum, so a doctor can feel the back surface of the prostate by inserting a gloved, lubricated finger into the rectum. The exam takes about 10–15 seconds.

DRE can detect hard lumps or irregularities that might suggest cancer. However, it has important limitations:⁶ ⁷

• It only feels the back part of the prostate. Cancers in the front or deep inside are missed.
• It is subjective — what one doctor feels, another might interpret differently.
• Sometimes what you feel is not cancer at all — it could be prostatitis (inflammation), a prostate stone (calcification), or a hemorrhoid.

Despite these limitations, DRE still has value. Rarely, a man can have prostate cancer with a completely normal PSA, and DRE may be the only clue. Current guidelines say DRE should not be used alone for screening, but it can be a useful addition to PSA, especially when PSA is elevated. A suspicious finding on DRE should at least prompt an MRI, particularly if PSA is also high.⁶ ⁷

What Are the Screening Guidelines?

Different medical organizations have slightly different recommendations, but they all agree on one thing: the decision to screen should involve a conversation between you and your doctor (shared decision-making). No organization recommends screening without first discussing the potential benefits and harms.¹ ² ³ ⁶ ⁷ ⁸

Here is a summary of the major guidelines:

US Preventive Services Task Force (USPSTF):²

• Ages 55–69: Discuss benefits and harms with your doctor; screening is an individual decision (Grade C recommendation).
• Age 70 and older: Screening is not recommended (Grade D recommendation).

American Urological Association (AUA):³ ⁷

• Ages 50–69 (average risk): Offer PSA screening every 2–4 years after shared decision-making.
• Ages 45–49 (average risk): Screening may be offered.
• Ages 40–45 (higher risk): Screening may be offered for those with Black ancestry, germline mutations (like BRCA2), or strong family history.
• Age 70 and older: Routine screening is not recommended.

American Cancer Society (ACS):⁸

• Age 50 (average risk): Discuss screening if life expectancy is at least 10 years.
• Age 45: Discuss screening for high-risk men (Black men, men with a first-degree relative diagnosed before age 65).
• Age 40: Discuss screening for very high-risk men (multiple first-degree relatives with early prostate cancer).
• PSA 2.5 ng/mL: Rescreen every 2 years. PSA ≥ 2.5 ng/mL: Rescreen every year.

National Comprehensive Cancer Network (NCCN):⁶

• Ages 45–75 (average risk): Baseline PSA and consider DRE. Screening intervals depend on PSA level:
• PSA 1 ng/mL: Retest every 2–4 years.
• PSA 1–3 ng/mL: Retest every 1–2 years.
• PSA > 3 ng/mL or suspicious DRE: Further evaluation (MRI, possible biopsy).
• Ages 40–75 (higher risk): Black/African American individuals, those with germline variants (like BRCA1/2), or concerning family history.
• Age > 75: Only in select, very healthy patients with little or no comorbidity (category 2B).

European Association of Urology (EAU):⁴

• Individualized, risk-adapted screening strategy for men with at least 10–15 years of life expectancy.
• 2-year intervals for men at elevated risk; up to 8-year intervals for men at lower risk.

Special Populations:

• Black/African American men have a significantly higher incidence of prostate cancer, are diagnosed at younger ages, and have higher mortality rates. These disparities are related to a greater incidence of preclinical prostate cancer, social determinants of health, and treatment disparities — not to race itself. Studies show that when Black patients receive equitable treatment, outcomes are similar to white patients. Many experts recommend Black men begin the screening conversation at age 40 and consider annual screening.⁶ ⁹
• Family history: If your father or brother had prostate cancer, especially if diagnosed young, your risk is higher. Sons of affected fathers should generally start screening earlier than the general population. If there is a known or suspected cancer susceptibility gene (like BRCA2), referral to a genetic counselor is recommended.⁶
• Transgender women and other gender-diverse individuals assigned male at birth retain their prostates regardless of gender-affirming surgery. They should undergo shared decision-making about screening. However, gender-affirming hormones like estrogen can drastically lower PSA levels (median PSA of 0.02 ng/mL in one study), so PSA values must be interpreted very cautiously in this population. Rising PSA levels deserve special attention.⁶

Should We Stop Screening at 75?

Most guidelines recommend against routine screening after age 75 (or 70, depending on the organization). The reasoning is:² ⁶ ¹⁰

• Prostate cancer usually grows slowly, and men over 75 are more likely to die of other causes.
• Screening in older men substantially increases overdiagnosis — finding cancers that would never have caused symptoms or death.
• The benefits of screening take about 10 years to materialize, so men with less than 10 years of life expectancy are unlikely to benefit.

However, this is not an absolute rule. The NCCN notes that testing after 75 should be considered only in very healthy individuals with little or no comorbidity, especially those who have never had PSA testing or who have a rising PSA. The decision should be individualized.⁶ ¹⁰

The Great Screening Debate: The European and US Studies

The question of whether PSA screening saves lives has been one of the most debated topics in medicine. Two landmark studies reached seemingly opposite conclusions, creating confusion for decades.

The European Study (ERSPC):

The European Randomized Study of Screening for Prostate Cancer enrolled over 162,000 men aged 55–69 across eight European countries starting in 1993. Men were randomly assigned to receive PSA screening (every 2–4 years, with a biopsy threshold of 3.0 ng/mL) or no screening.¹¹ ¹²

Results at 23 years of follow-up (published in 2025):¹¹

• Prostate cancer mortality was 13% lower in the screening group (rate ratio 0.87; 95% CI, 0.80–0.95).
• The absolute risk reduction was 0.22% — meaning for every 456 men invited for screening, one death from prostate cancer was prevented.
• For every 12 men diagnosed with prostate cancer through screening, one death was prevented.
• However, screening also led to overdiagnosis: the cumulative incidence of prostate cancer was 30% higher in the screening group.
• The harm-to-benefit ratio improved over time compared to earlier reports.

The Rotterdam section of the ERSPC, with 21 years of follow-up, showed an even stronger effect: a 27% reduction in prostate cancer mortality (rate ratio 0.73) and a 33% reduction in metastatic disease (rate ratio 0.67). The number needed to invite to prevent one death was 246, and the number needed to diagnose was 14.¹³

The US Study (PLCO):

The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial enrolled about 76,700 men aged 55–74 in the US. Men were randomized to annual PSA screening or usual care.¹⁴ ¹⁵

Results: No significant difference in prostate cancer mortality between the two groups (rate ratio 0.93; 95% CI, 0.81–1.08 at 17 years).¹⁵

But here is the critical problem: contamination. An estimated 78% of men in the "usual care" (control) group were already getting PSA tests on their own outside the study. On average, men in the control group received 3 PSA tests during the screening phase. So the study was essentially comparing organized screening to widespread opportunistic screening.² ¹⁴ ¹⁵ A modeling exercise estimated that with lower contamination, the PLCO results would have been consistent with a 27–32% reduction in prostate cancer mortality — similar to the European study.¹¹ ¹⁶

The CAP Trial (UK):

A third major trial in England and Wales tested a single PSA screening invitation in men aged 50–69. At 15 years, there was a small, non-significant reduction in prostate cancer mortality (rate ratio 0.92; 95% CI, 0.83–1.01), but the study used only a single screening test (not repeated screening), and adherence was limited.¹⁷

The 2026 Meta-Analysis:

A systematic review and meta-analysis of 5 randomized trials (721,607 participants, 11–23 years of follow-up) published in European Urology in 2026 concluded with high certainty that PSA-based screening is associated with reduced prostate cancer-specific mortality among individuals who engage in screening. The authors noted that this finding contrasts with earlier evidence syntheses and that the benefit should be weighed against known harms.¹⁸

The USPSTF Response:

In 2012, the USPSTF initially recommended against PSA screening for all men (Grade D), based largely on the PLCO results and concerns about overdiagnosis and overtreatment. This was controversial and led to a decline in screening rates and, some argue, an increase in men presenting with advanced disease. In 2018, the USPSTF revised its recommendation to a Grade C for men aged 55–69 — meaning screening should be an individual decision after shared decision-making. Screening is still not recommended for men 70 and older. The USPSTF guideline is currently being updated.² ¹

The Bottom Line:

The best available evidence now confirms that organized PSA screening does reduce prostate cancer deaths, but at the cost of overdiagnosis and overtreatment.¹¹ ¹⁸ The key is not whether to screen, but how to screen smarter — using risk-based approaches, better biomarkers, and MRI to reduce unnecessary biopsies and find the cancers that truly matter.¹⁹

Many Patients with High PSA Do Not Have Cancer

This is one of the most important things to understand about PSA. A high PSA does not mean you have cancer. In fact:²⁰

• Only about 30–35% of men with a PSA between 4 and 10 ng/mL will have cancer found on biopsy.
• Even 15% of men with a PSA ≤ 4.0 ng/mL have prostate cancer on biopsy (as shown in the Prostate Cancer Prevention Trial).
• PSA levels > 10 ng/mL carry a > 67% likelihood of prostate cancer.

Among men with a new, moderately elevated PSA level (4–10 ng/mL), the PSA level decreases to the normal range in 25–40% of men when retested; therefore, a repeat PSA test to confirm elevation should be performed, typically within a few months.¹

Many of the cancers found through screening are low-grade (Gleason 6 / Grade Group 1), which are very unlikely to cause harm and may never need treatment. This is the overdiagnosis problem — finding cancers that would have been better left undiscovered. This is why additional tools (biomarkers, MRI) are so important to help determine which elevated PSAs truly need a biopsy.⁴ ²⁰

Understanding PSA in Detail

What Can Increase PSA?

Many things besides cancer can raise your PSA level:⁵ ²¹ ²²

• Benign prostatic hyperplasia (BPH): An enlarged prostate produces more PSA. This is the most common cause of mildly elevated PSA.
• Prostatitis (prostate infection/inflammation): Can cause dramatic PSA elevations that may take weeks or months to return to normal.
• Urinary tract infection (UTI): Inflammation near the prostate can raise PSA.
• Recent ejaculation: Can cause a minor increase (less than 1.0 ng/mL) that resolves within 48 hours.²³ ²⁴
• Prostate procedures: Biopsy, TURP (transurethral resection of the prostate), cystoscopy, or catheter placement can raise PSA significantly. After a biopsy or TURP, PSA can rise dramatically and remain elevated for 2–6 weeks.⁵
• Vigorous exercise: Particularly cycling, may temporarily raise PSA. A randomized study of 101 men found that changes in PSA due to moderate cycling and rowing are generally minimal and clinically irrelevant, though in a few men, pronounced increases can occur.²⁵
• Acute urinary retention: Can elevate PSA.⁵
• Testosterone replacement therapy (TRT): Can increase PSA. Men on TRT need regular PSA and DRE monitoring. If PSA changes significantly, most doctors would stop TRT and evaluate further. PSA typically drops after stopping TRT.

What Can Decrease PSA?

• 5-alpha reductase inhibitors (finasteride, dutasteride): These medications, used for BPH and hair loss, decrease PSA by approximately 50%. If you are on these medications, your PSA value should be doubled (multiplied by 2) to get the "true" level.⁶
• Obesity: Higher BMI is associated with lower PSA levels, possibly due to hemodilution (more blood volume diluting the PSA).
• Statins: Long-term use may lower PSA by about 13% after 5 years.²⁶
• NSAIDs (like aspirin, ibuprofen): May modestly lower PSA (about 6% after 5 years).²⁶
• Thiazide diuretics: May lower PSA by up to 26% after 5 years. The combination of statins and thiazide diuretics showed the greatest reduction: 36% after 5 years.²⁶
• Gender-affirming hormones (estrogen): Can dramatically lower PSA in transgender women.⁶

Practical Advice Before a PSA Test:

• Avoid ejaculation for at least 48 hours before the test.²³
• Avoid vigorous exercise (especially cycling) for 48 hours.²⁵
• If you recently had a DRE, catheter, cystoscopy, or prostate biopsy, wait the appropriate time before checking PSA (ask your doctor).
• Tell your doctor about all medications you take, especially finasteride, dutasteride, statins, and NSAIDs.
• Try to use the same laboratory each time for consistency.⁵

PSA Variations: Beyond the Basic Number

Doctors have developed several ways to make PSA more useful beyond just the total number:

PSA Density (PSAD):

This is your PSA level divided by the volume (size) of your prostate, measured by ultrasound or MRI. Why does this matter? A large prostate naturally produces more PSA. A PSA of 6 ng/mL in a man with a 100-gram prostate (density = 0.06) is much less concerning than a PSA of 6 in a man with a 30-gram prostate (density = 0.20). Higher PSA density is associated with a greater risk of clinically significant cancer.²⁰

PSA Velocity:

This measures how fast your PSA is rising over time. A rapid rise may be more concerning than a stable, mildly elevated PSA. The NCCN notes that persistent acceleration in PSA over and above an established baseline is concerning for high-risk prostate cancer. Patients with a persistent and significant increase in PSA should be encouraged to undergo biopsy, including patients with a higher PSA density, even if they have a normal MRI.²⁰

Free PSA and Percent Free PSA:

PSA circulates in the blood in two forms: "free" (floating alone) and "bound" (attached to proteins). Cancer cells tend to produce more bound PSA, so a lower percentage of free PSA suggests a higher risk of cancer. For example, if your total PSA is 6 ng/mL and your percent free PSA is 10%, that is more concerning than if your percent free PSA is 25%. This test is most useful in the "gray zone" of PSA between 4 and 10 ng/mL.²⁰ ²⁷

Age-Specific PSA Reference Ranges:

Because PSA naturally increases with age (due to prostate growth), some doctors use age-adjusted thresholds:⁵

• Age 40–49: up to 2.5 ng/mL
• Age 50–59: up to 3.5 ng/mL
• Age 60–69: up to 4.5 ng/mL
• Age 70–79: up to 6.5 ng/mL

The NCCN notes that median PSA values for men aged 40–49 range from 0.5–0.7 ng/mL. Men with PSA above the median for their age are at higher risk for prostate cancer and aggressive disease.⁶

Biomarkers: Smarter Tests to Decide If You Need a Biopsy

A biomarker is any measurable substance that provides information about a disease. PSA itself is a biomarker, but it is not perfect. Newer biomarkers have been developed to help answer a critical question: "My PSA is elevated — do I really need a biopsy, or can I safely wait?"²⁸ ²⁹

These tests are most useful in two situations:

1. Before a first biopsy: To help decide if a biopsy is truly needed when PSA is elevated.
2. After a negative biopsy: When PSA remains elevated but the first biopsy did not find cancer.

The NCCN emphasizes that patients who meet PSA standards for consideration of biopsy should undergo multiparametric MRI (mpMRI) first (category 1). Biomarkers (category 2B) can be considered if mpMRI is not available, contraindicated, or inconclusive, or if the patient and physician wish to more precisely estimate risk.²⁸

A meta-analysis of studies included in the AUA guideline showed that use of secondary biomarkers would reduce the number of biopsies by approximately 35%, while approximately 9% of clinically significant prostate cancers would not be detected.²⁹

Here are the main biomarker tests available:

Blood-Based Tests:

• Prostate Health Index (PHI): Combines three forms of PSA (total PSA, free PSA, andproPSA) into a single score. FDA-approved. More accurate than PSA alone at predicting clinically significant cancer.²⁸ ³⁰ ³¹^[1]
• 4Kscore: Measures four kallikrein proteins in the blood to estimate the risk of aggressive prostate cancer. FDA-approved (2015). A meta-analysis found that 4Kscore had the highest diagnostic performance among commercial liquid biomarkers for detecting clinically significant prostate cancer.³⁰ ³¹ ³²
• IsoPSA: Measures the structural characteristics of PSA protein rather than its concentration. Can help distinguish cancer from benign conditions.²⁸
• Stockholm3 (STHLM3): A risk prediction model combining blood proteins, genetic markers, and clinical data. Validated in European populations.²⁸

Urine-Based Tests (some require a DRE or prostate massage before collection):

• PCA3 (PROGENSA): Measures PCA3 mRNA, which is overexpressed in prostate cancer cells but not in normal prostate tissue. FDA-approved (2012). Originally designed to help decide about repeat biopsies after a negative first biopsy. More specific than PSA but does not distinguish well between low-risk and aggressive disease.³⁰ ³¹
• SelectMDx: A urine test that measures two genes (HOXC6 and DLX1) to estimate the risk of high-grade prostate cancer. Helps decide whether a biopsy is needed.²⁸ ³²
• ExoDx Prostate (IntelliScore / EPI): Analyzes exosomes (tiny particles released by cells) in urine. Does not require a DRE before collection. Predicts the risk of high-grade cancer.²⁸ ³²
• MyProstateScore (MPS) and MPS 2.0: Combines PSA and PCA3 with other urinary biomarkers. Validated for predicting clinically significant cancer.²⁸

Tissue-Based Test (after biopsy):

• ConfirmMDx: An epigenetic test performed on tissue from a negative biopsy. Looks for DNA methylation changes that suggest cancer may be present nearby, even though the biopsy needle missed it. Helps decide if a repeat biopsy is needed.²⁸ ³³

How do these biomarkers compare?

A systematic review and meta-analysis of 49 studies found the following diagnostic performance for detecting clinically significant prostate cancer (Grade Group ≥ 2):³²

• 4Kscore: Sensitivity 87%, specificity 58% — highest diagnostic odds ratio (8.84)
• PHI: Sensitivity 85%, specificity 52% — highest specificity when using multiple thresholds
• SelectMDx: Sensitivity 82%, specificity 56%
• ExoDx: Sensitivity 85%, specificity 54%
• MPS: Sensitivity 82%, specificity 59%
• PCA3: Sensitivity 85%, specificity 37% — lowest diagnostic performance overall

In general, these tests are calibrated so that avoiding biopsy in the setting of a sub-threshold test reduces biopsies by about one-third, resulting in delayed detection or non-detection of 5–10% of clinically significant prostate cancers.²⁹

Important Cautions About Biomarkers:

The NCCN warns that these tests have variable validation across diverse populations, are mostly supported by retrospective observational studies (often with industry support), and should not be used in place of MRI. There is a risk that biomarker tests may underestimate risk, leading to delayed or missed diagnoses. They are best used as one piece of the puzzle, alongside PSA, DRE, MRI, and clinical judgment.²⁸

Liquid Biopsy and Multi-Cancer Early Detection Tests

An exciting area of research is the development of liquid biopsies — blood tests that can detect traces of cancer by analyzing circulating tumor DNA (ctDNA), circulating tumor cells, or other molecules shed by tumors into the bloodstream.

Multi-Cancer Early Detection (MCED) Tests:

The most well-known is the Galleri test (by GRAIL), which analyzes DNA methylation patterns in cell-free DNA from a blood draw. It can potentially detect over 50 types of cancer and predict which organ the cancer signal is coming from.³⁴

In a study of over 111,000 individuals, the Galleri test detected a cancer signal in 0.91% of people tested. Among those with a confirmed cancer diagnosis, the test correctly predicted the organ of origin in 87% of cases.³⁵ However, overall sensitivity was moderate (about 51.5%), meaning it misses about half of cancers, especially early-stage ones. Specificity was very high (99.5%), meaning false positives are rare.³⁴

Galleri and prostate cancer specifically:

An important study published in JCO Precision Oncology found that the Galleri test preferentially detects high-grade, clinically significant prostate cancer while minimizing overdiagnosis of indolent disease. In the CCGA validation study, overall sensitivity for prostate cancer was only 11.2%, but the test detected 0% of Grade Group 1 (low-grade) cancers, 1.9% of Grade Group 2, 5.1% of Grade Group 3, and 31.9% of Grade Group 4–5 (high-grade) cancers. This means the test is unlikely to worsen the overdiagnosis problem.³⁶

A real-world experience from Mass General Brigham found that prostate cancer was diagnosed in multiple patients after a negative MCED test, consistent with the test's limited sensitivity for prostate cancer.³⁷

The NHS-Galleri Trial:

A large randomized trial in England enrolled over 140,000 healthy individuals to determine whether the Galleri test can reduce late-stage cancer diagnoses. The trial's primary endpoint — a significant reduction in stage 3 and 4 cancers — was not met at the end of the study, though the company reported a reduction in stage 4 diagnoses for a prespecified group of 12 cancers. The question of whether MCED tests actually reduce cancer deaths remains unanswered.³⁸ ³⁹

Important Limitations:³⁴ ³⁸ ³⁹

• MCED tests are not yet standard of care for prostate cancer screening.
• They are better at detecting advanced cancers than early-stage ones.
• They do not replace PSA screening for prostate cancer.
• The Galleri test is available in the US as a laboratory-developed test with out-of-pocket cost, but it is not FDA-approved and is not covered by insurance for routine screening.
• More research is needed to determine whether these tests actually reduce cancer deaths.

PET or MRI Screening?

Currently, neither PET scans nor MRI are recommended as routine screening tools for prostate cancer in the general population. However:⁶ ²⁰

• MRI is increasingly used as a next step after an elevated PSA to help decide whether a biopsy is needed and to guide where to biopsy. The NCCN recommends multiparametric MRI (mpMRI) as a category 1 recommendation when PSA meets criteria for biopsy consideration, including PSA density assessment. MRI is not a screening test — it is a diagnostic tool used after screening raises concern.
• Micro-ultrasound guided biopsy performed at expert centers was found to be non-inferior to MRI-targeted fusion biopsy for the detection of clinically significant prostate cancer in a 2025 JAMA study.²⁰
• PET scans (like PSMA-PET) are used for staging and detecting recurrence, not for initial screening. They are discussed in detail in Chapter 5 (Imaging).

Ongoing Research in Screening

The field of prostate cancer screening is evolving rapidly. Some areas of active research include:

• Risk-adapted screening: Using genetic risk scores (polygenic risk scores), family history, race, and baseline PSA to personalize when to start screening, how often to screen, and when to stop. A microsimulation study comparing the EAU risk-adapted protocol (PSA-based intervals, risk calculator, and MRI) to the ERSPC protocol found that the EAU approach significantly reduced biopsies and overdiagnosis while maintaining equal prostate cancer mortality.¹⁹
• MRI as a screening tool: Some researchers are exploring whether MRI could be used earlier in the screening pathway, potentially replacing or supplementing PSA.
• Artificial intelligence: AI algorithms are being developed to better interpret PSA trends, MRI images, and biomarker results to improve screening accuracy.
• Combination biomarker panels: Combining multiple blood and urine markers with clinical data to create more accurate risk prediction models.²⁸ ³²
• The Stockholm3 model: A validated risk prediction tool combining blood proteins, genetic markers, and clinical variables that has shown promise in reducing unnecessary biopsies while maintaining detection of significant cancers.²⁸

Questions to Ask Your Doctor

1. Based on my age, race, family history, and overall health, should I be screened for prostate cancer?
2. What is my PSA level, and what does it mean for someone my age?
3. If my PSA is elevated, what are the next steps before considering a biopsy?
4. Should I get an MRI before a biopsy?
5. Are there any biomarker tests that could help clarify my risk?
6. I am on [finasteride / dutasteride / statins / testosterone] — how does this affect my PSA?
7. At what point should I stop screening?
8. What are the risks of screening, and what happens if we find something?

Myth vs. Fact

• Myth: "If my PSA is normal, I definitely don't have prostate cancer."

Fact: About 15% of men with a PSA ≤ 4.0 ng/mL have prostate cancer. PSA is a helpful tool, but it is not perfect. Some cancers do not raise PSA significantly.²⁰

• Myth: "A high PSA means I have cancer."

Fact: Most men with a mildly elevated PSA (4–10 ng/mL) do NOT have cancer. Only about 30–35% will have cancer found on biopsy. BPH, infection, and other factors are more common causes.²⁰

• Myth: "Prostate cancer screening is no longer recommended."

Fact: Screening is recommended as a shared decision between you and your doctor for men aged 55–69 (USPSTF) or 45–75 (NCCN). The 2012 recommendation against screening was reversed in 2018. A 2026 meta-analysis of 5 randomized trials confirmed with high certainty that PSA screening reduces prostate cancer deaths.² ¹⁸

• Myth: "If I get screened and they find cancer, I'll definitely need surgery or radiation."

Fact: Many prostate cancers found through screening are low-grade and can be safely monitored with active surveillance — no immediate treatment needed. Screening finds the cancer; it does not force you into treatment.⁶

• Myth: "Screening is only for older men."

Fact: Men at higher risk — including Black men, those with a family history, and those with known genetic mutations like BRCA2 — should discuss screening as early as age 40.⁶ ⁸

• Myth: "A DRE can find all prostate cancers."

Fact: DRE only feels the back surface of the prostate. Cancers in the front, deep inside, or in the transition zone are missed. DRE is a useful addition to PSA but cannot replace it.⁷

• Myth: "The new multi-cancer blood tests (like Galleri) can replace PSA screening."

Fact: MCED tests detect only about 11% of prostate cancers overall and are much better at finding advanced disease than early-stage cancer. They do not replace PSA screening and are not yet standard of care.³⁶

Key Takeaways

1. Prostate cancer screening means testing for cancer before you have symptoms, using a PSA blood test and sometimes a digital rectal exam (DRE).
2. Screening is not a simple yes or no — it is a conversation with your doctor about your personal risk factors, values, and preferences (shared decision-making).
3. PSA is a useful but imperfect test. Many things besides cancer can raise PSA, and not all cancers raise PSA. A high PSA does not mean you have cancer.
4. The best evidence now confirms that organized PSA screening reduces prostate cancer deaths, but it also leads to overdiagnosis of slow-growing cancers that may never cause harm.
5. Newer biomarker tests (PHI, 4Kscore, SelectMDx, ExoDx, and others) and MRI can help determine which men with elevated PSA truly need a biopsy, reducing unnecessary procedures by about one-third.
6. Black men, men with a family history of prostate cancer, and those with known genetic mutations should start the screening conversation earlier (age 40–45) and may benefit from more frequent testing.
7. Screening is generally not recommended after age 75, but exceptions exist for very healthy men with no prior screening.

Support Resources

• American Cancer Society — Prostate Cancer Screening: cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/tests.html
• ZERO — The End of Prostate Cancer: zerocancer.org — Free screening events, education, and support.
• Prostate Cancer Foundation: pcf.org — Patient guides on screening and early detection.
• NCCN Patient Guidelines — Prostate Cancer Early Detection: nccn.org/patients — Free, detailed guidelines written for patients.
• Us TOO International: ustoo.org — Peer support and education for prostate cancer patients and families.
• CDC — Prostate Cancer Screening: cdc.gov/cancer/prostate — Information on screening decisions.
• Know Your Risk Tool (NCCN): Tools to help assess your personal risk and screening needs.

References

1. 1. Brown MM, Adams CA, Halpert KD. Cancer screening in older adults. American Family Physician. 2025;112(6):629–637.
2. 2. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–1913.
3. 3. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. Journal of Urology. 2013;190(2):419–426.
4. 4. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer — 2024 update. European Urology. 2024;86(2):148–163.
5. 5. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. Journal of Urology. 1994;151(5):1283–1290.
6. 6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2026.
7. 7. American Urological Association. Early detection of prostate cancer guideline (2023 amendment). aua.org.
8. 8. American Cancer Society. Prostate cancer early detection recommendations. cancer.org. Updated 2024.
9. 9. Dess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncology. 2019;5(7):975–983.
10. 10. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285(21):2750–2756.
11. 11. Hugosson J, Roobol MJ, Månsson M, et al. A 23-year follow-up of the European Randomized Study of Screening for Prostate Cancer. New England Journal of Medicine. 2025;393(26):2529–2540.
12. 12. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. New England Journal of Medicine. 2009;360(13):1320–1328.
13. 13. Roobol MJ, Kranse R, Bangma CH, et al. Screening for prostate cancer: results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer at 21 years of follow-up. European Urology. 2024;85(4):357–365.
14. 14. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. New England Journal of Medicine. 2009;360(13):1310–1319.
15. 15. Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592–599.
16. 16. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Annals of Internal Medicine. 2017;167(7):449–455.
17. 17. Martin RM, Donovan JL, Turner EL, et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319(9):883–895.
18. 18. Frånlund M, Månsson M, Godtman RA, et al. Systematic review and meta-analysis of randomized trials on prostate cancer screening. European Urology. 2026;89(3):312–321.
19. 19. de Vos II, Roobol MJ, Heijnsdijk EAM."; Microsimulation modeling of the EAU risk-adapted screening protocol. European Urology. 2024;86(1):45–52.
20. 20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 5.2026.
21. 21. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. Journal of Urology. 1995;154(2 Pt 1):407–413.
22. 22. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270(7):860–864.
23. 23. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. 1997;50(2):239–243.
24. 24. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology. 1996;47(4):511–516.
25. 25. Mejak SL, Bayliss J, Hanks SD. Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over. PLoS One. 2013;8(2):e56030.
26. 26. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. Journal of Clinical Oncology. 2010;28(25):3951–3957.
27. 27. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998;279(19):1542–1547.
28. 28. National Comprehensive Cancer Network. NCCN Guidelines: Principles of Risk Stratification and Biomarkers (PROS-H). Version 5.2026.
29. 29. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I and II. Journal of Urology. 2023;210(1):46–53.
30. 30. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Therapeutic Advances in Urology. 2014;6(2):74–77.
31. 31. Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M. Comparison between the four-kallikrein panel and Prostate Health Index for predicting prostate cancer. European Urology. 2015;68(1):139–146.
32. 32. Hendriks RJ, van Oort IM, Schalken JA. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer and Prostatic Diseases. 2017;20(1):12–19.
33. 33. Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. European Urology. 2016;70(5):740–748.
34. 34. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of Oncology. 2020;31(6):745–759.
35. 35. Schrag D, Beer TM, McDonnell CH III, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251–1260.
36. 36. Chung JH, Pavlick D, Hartmaier R, et al. Cell-free DNA multi-cancer early detection test preferentially detects clinically significant prostate cancer. JCO Precision Oncology. 2023;7:e2300092.
37. 37. Botta GP, Abdelrahim M, Dumbrava EI, et al. Real-world experience with multi-cancer early detection testing at Mass General Brigham. Cancer Discovery. 2024;14(6):987–995.
38. 38. Neal RD, Johnson P, Clarke CA, et al. Cell-free DNA-based multi-cancer early detection test results in 323 cancers in the NHS-Galleri trial. Annals of Oncology. 2025;36(3):282–291.
39. 39. Hackshaw A, Clarke CA, Hartman AR, et al. NHS-Galleri trial: design and results of a multi-cancer early detection screening trial. Lancet. 2025;405(10483):1155–1166.
40. 40. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine. 1991;324(17):1156–1161.
41. 41. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. New England Journal of Medicine. 2004;350(22):2239–2246.
42. 42. Klotz L, Pond G, Loblaw A, et al. Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. European Urology. 2020;77(3):311–317.